TaxTMI Login
Just a moment...
Press 'Enter' to add multiple search terms. Rules for Better Search
When case Id is present, search is done only for this
of 
of 
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
of of 
All Case Laws
of of All Case Laws
Note
Bookmark
Share
Don't have an account? Register Here
of <h1>Classification of Medicaments: Labeling Impact on Tariff</h1> <h3>OBOI LABORATORIES Versus COMMISSIONER OF CENTRAL EXCISE, MUMBAI</h3> The Tribunal partially allowed the appeal regarding the classification of medicaments under the Central Excise Tariff Act. The product displaying a house ... Medicaments - P or P medicaments Issues: Classification of medicaments under Central Excise Tariff ActAnalysis:The appeal involved the classification of two medicaments, Obroquin Injection 30 ml and Cloroquine Phosphate Injection 30 ml, under the Central Excise Tariff Act. The appellant claimed classification of the goods as patent and proprietary medicines under Heading 3003.10, while the department contended that they should be classified under Heading 3003.20 based on the Supreme Court's decision in the case of Astra Pharmaceuticals v. CCE, Chandigarh. The Commissioner (Appeals) classified the products under Heading 3003.20, citing the conspicuous display of generic names on the labels.Upon review, the Tribunal found that the patented name 'Obroquin' was prominently displayed on one product's label, while the other product lacked a house name. Disagreeing with the Commissioner's view that the generic name's conspicuous mention indicated generic medicines, the Tribunal ruled that the presence of a house name on one product's label warranted classification under Heading 3003.10 for Obroquin and under Heading 3003.20 as a generic medicine for Chloroquine Phosphate. The appeal was partially allowed for products with a house name and rejected for the product displaying only the generic name on the label, leading to their respective classifications under 3003.10 and 3003.20 of the Schedule to CETA.This judgment clarifies the classification criteria for medicaments under the Central Excise Tariff Act, emphasizing the significance of house names and generic names displayed on product labels in determining the appropriate classification under specific headings. The decision underscores the importance of clear labeling practices in differentiating between patent and proprietary medicines and generic medicines for classification purposes, providing guidance for future classification disputes in the pharmaceutical industry.
TaxTMI 
TaxTMI 
